BAVARIAN NORDIC/S (OTCMKTS:BVNRY) is scheduled to post its quarterly earnings results before the market opens on Friday, November 9th. Analysts expect BAVARIAN NORDIC/S to post earnings of ($0.14) per share for the quarter.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last released its quarterly earnings data on Thursday, August 16th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). BAVARIAN NORDIC/S had a negative net margin of 18.41% and a negative return on equity of 6.60%. The firm had revenue of $13.83 million during the quarter, compared to analysts’ expectations of $10.40 million. On average, analysts expect BAVARIAN NORDIC/S to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

BVNRY opened at $7.76 on Thursday. BAVARIAN NORDIC/S has a fifty-two week low of $7.41 and a fifty-two week high of $14.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.35 and a quick ratio of 5.07. The firm has a market capitalization of $748.30 million, a price-to-earnings ratio of 26.76 and a beta of 1.20.

BVNRY has been the subject of a number of research reports. ValuEngine raised shares of BAVARIAN NORDIC/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Zacks Investment Research raised shares of BAVARIAN NORDIC/S from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Wednesday, August 22nd.

WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Featured Article: Buyback For Investors Defined


Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.